Bide Pharmatech Co., Ltd. (SHA:688073)
China · Delayed Price · Currency is CNY 61.93
+3.65 (6.26%)
At close: Feb 3, 2026
Bide Pharmatech Revenue
Bide Pharmatech had revenue of 351.58M CNY in the quarter ending September 30, 2025, with 25.94% growth. This brings the company's revenue in the last twelve months to 1.27B, up 15.62% year-over-year. In the year 2024, Bide Pharmatech had annual revenue of 1.10B with 0.93% growth.
Revenue (ttm)
1.27B
Revenue Growth
+15.62%
P/S Ratio
4.20
Revenue / Employee
1.72M
Employees
129
Market Cap
5.34B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.10B | 10.15M | 0.93% |
| Dec 31, 2023 | 1.09B | 258.03M | 30.94% |
| Dec 31, 2022 | 833.83M | 227.61M | 37.55% |
| Dec 31, 2021 | 606.22M | 214.75M | 54.86% |
| Dec 31, 2020 | 391.46M | 142.87M | 57.47% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ZhuZhou QianJin Pharmaceutical Co.,Ltd | 3.63B |
| Jianmin Pharmaceutical Group | 3.18B |
| Luoxin Pharmaceuticals Group Stock | 2.49B |
| Hunan Fangsheng Pharmaceutical | 1.68B |
| Zhuhai Rundu Pharmaceutical | 1.19B |
| Tibet Weixinkang Medicine | 1.17B |
| Newland Pharmaceutical | 670.43M |
| Nanjing Hicin Pharmaceutical | 615.39M |